Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 2 records in total 2
    records per page

    Characterisation of Acute Kidney Injury MESHD Acute Kidney Injury HP in Critically Ill Patients with Severe Coronavirus Disease MESHD-2019 (COVID-19)

    Authors: Sebastien RUBIN; Arthur Orieux; Renaud Prevel; Antoine Garric; Marie-Lise Bats; Sandrine Dabernat; Fabrice Camou; Olivier Guisset; Nahema Issa; Gaelle Mourissoux; Antoine Dewitte; Olivier Joannes-boyau; Catherine Fleureau; Hadrien Roze; Cedric Carrie; Laurent Petit; Benjamin Clouzeau; Charline Sazio; Hoang-Nam Bui; Odile Pillet; Claire Rigothier; Frederic Vargas; Christian Combe; Didier Gruson; Alexandre Boyer

    doi:10.1101/2020.05.06.20069872 Date: 2020-05-10 Source: medRxiv

    Background: COVID19-associated acute kidney injury MESHD acute kidney injury HP frequency, severity and characterisation in critically ill patients has not been reported. Methods: Single-center cohort performed from March 3, 2020, to April 14, 2020 in 4 intensive care units in Bordeaux University Hospital, France. All patients with COVID19 and pulmonary severity criteria were included. AKI was defined using KDIGO criteria. A systematic urinary analysis was performed. The incidence, severity, clinical presentation, biological characterisation (transient vs. persistent acute kidney injury MESHD acute kidney injury HP; proteinuria MESHD proteinuria HP, hematuria MESHD hematuria HP and glycosuria MESHD glycosuria HP), and short-term outcomes was evaluated. Results: 71 patients were included, with basal serum SERO creatinine of 69 +/- 21 micromol/L. At admission, AKI was present in 8/71 (11%) patients. Median follow-up was 17 [12-23] days. AKI developed in a total of 57/71 (80%) patients with 35% Stage 1, 35% Stage 2, and 30% Stage 3 acute kidney injury MESHD acute kidney injury HP; 10/57 (18%) required renal replacement therapy. Transient AKI was present in only 4/55 (7%) patients and persistent AKI was observed in 51/55 (93%). Patients with persistent AKI developed a median urine protein/creatinine of 82 [54-140] (mg/mmol) with an albuminuria MESHD albuminuria HP/ proteinuria MESHD proteinuria HP ratio of 0.23 +/- 20 indicating predominant tubulo-interstitial injury. Only 2 (4%) patients had glycosuria MESHD glycosuria HP. At Day 7 onset of after AKI, six (11%) patients remained dependent on renal replacement therapy, nine (16%) had SCr > 200 micromol/L, and four (7%) died. Day 7 and day 14 renal recovery occurred in 28% and 52 % respectively. Conclusion: COVID19 associated AKI is frequent, persistent severe and characterised by an almost exclusive tubulo-interstitial injury without glycosuria MESHD glycosuria HP

    SARS-CoV-2 infection MESHD does not significantly cause acute renal injury: an analysis of 116 hospitalized patients with COVID-19 in a single hospital, Wuhan, China

    Authors: Lunwen Wang; Xun Li; Hui Chen; Shaonan Yan; Yan Li; Dong Li; Zuojiong Gong

    doi:10.1101/2020.02.19.20025288 Date: 2020-02-23 Source: medRxiv

    Summary Background Whether the patients with COVID-19 infected by SARS-CoV-2 would commonly develop acute renal function damage is a problem worthy of clinical attention. This study aimed to explore the effects of SARS-CoV-2 infection MESHD on renal function through analyzing the clinical data of 116 hospitalized COVID-19-confirmed patients. Methods 116 hospitalized COVID-19-confirmed patients enrolled in this study were hospitalized in the Department of Infectious Diseases MESHD, Renmin Hospital of Wuhan University from January 14 to February 13, 2020. The recorded information includes demographic data, medical history, contact history, potential comorbidities, symptoms, signs MESHD, laboratory test results, chest computer tomography (CT) scans, and treatment measures. SARS-CoV-2 RNA in 53 urine sediments of enrolled patients was examined by real-time RT-PCR. Findings 12 (10.8%) and 8 (7.2%) patients showed mild elevation of blood SERO urea nitrogen or creatinine, and trace TRANS or 1+ albuminuria MESHD albuminuria HP respectively in 111 COVID-19-confirmed patients without basic kidney disease MESHD. In addition, 5 patients with chronic renal failure (CRF) were undergone regular continuous renal replacement therapy (CRRT) were confirmed infection TRANS infection MESHD of SARS-CoV-2, and diagnosed as COVID-19. Beside the treatment of COVID-19, CRRT was also applied three times weekly. The course of treatment, the renal function indicators showed stable, without exacerbation of CRF, and pulmonary inflammation MESHD was gradually absorbed. All 5 patients with CRF were survived. Moreover, SARS-CoV-2 RNA in urine sediments was positive only in 3 patients from 48 cases without renal illness before, and one patient had a positive for SARS-CoV-2 ORF 1ab from 5 cases with CRF. Interpretation Acute renal impairment was uncommon in COVID-19. SARS-CoV-2 infection MESHD does not significantly cause obvious acute renal injury, or aggravate CRF in the COVID-19 patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.